PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

Catalano, Onofrio A.; Horn, Gary Lloyd; Signore, Alberto; Iannace, C; Lepore, Maria; Vangel, Mark; Luongo, Antonella; Catalano, Marco; Lehman, Constance; Salvatore, Marco; Soricelli, Andrea; Catana, Ciprian; Mahmood, Umar; Rosen, Bruce R.

doi:10.1038/bjc.2017.26

Cited by 56 publications

(41 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors found that estrogen receptor (ER) and progesterone receptor (PR)‐negative tumors had higher SUV max and K ep than ER or PR‐positive tumors; that HER2‐negative tumors had higher apparent diffusion coefficient (ADC) mean , K ep , and SUV max values; and that tumors with lower levels of Ki67 showed lower ADC mean , but not greater K trans , as seen in the Margolis et al study . PET/MR markers correlated with immunohistochemical (IHC) phenotype in 62%, a promising beginning …”

Section: Index Lesion Evaluationmentioning

confidence: 80%

“…Catalano et al investigated whether 18 F‐FDG PET/MR could differentiate between histological phenotypes of breast cancer in 21 patients with invasive ductal carcinoma (IDC) . The authors found that estrogen receptor (ER) and progesterone receptor (PR)‐negative tumors had higher SUV max and K ep than ER or PR‐positive tumors; that HER2‐negative tumors had higher apparent diffusion coefficient (ADC) mean , K ep , and SUV max values; and that tumors with lower levels of Ki67 showed lower ADC mean , but not greater K trans , as seen in the Margolis et al study .…”

Section: Index Lesion Evaluationmentioning

confidence: 99%

See 1 more Smart Citation

PET/MRI in Breast Cancer

Pujara

Kim

Axelrod

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Index Lesion Evaluationmentioning

confidence: 80%

Section: Index Lesion Evaluationmentioning

confidence: 99%

PET/MRI in Breast Cancer

Pujara

Kim

Axelrod

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…From this, the areas where evidence exists that PET/MRI has been demonstrated to provide better information and characterisation of disease are in prostate cancer [ 23 ] and, as suggested previously at these workshops, in paediatric oncology [ 42 ]. Areas where new evidence is emerging include gastrointestinal cancers [ 43 , 44 ], breast cancer [ 40 , 41 ], gynaecological malignancies [ 37 ] and hepato-pancreatobiliary cancers [ 45 ]. The value of PET/MRI in these applications was seen again to be in a comprehensive regional evaluation and not in “whole-body” applications; as stated by one of the panellists: “The added value of PET/MRI starts locally”.…”

Section: Dialogue Boardsmentioning

confidence: 99%

Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany

et al. 2017

View full text Add to dashboard Cite

The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.

show abstract

“…The pharmacokinetic DCE-MRI parameters can be further correlated with metastatic status, Ki67 expression ( 38 ), and prognosis ( 39 , 40 ). Catalano et al demonstrated that 18 F-FDG PET/MRI could distinguish between molecular subtypes in 13/21 breast cancer patients ( 41 ).…”

Section: Pet-based Imaging Techniquesmentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

Cited by 56 publications

References 43 publications

PET/MRI in Breast Cancer

PET/MRI in Breast Cancer

Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Contact Info

Product

Resources

About